Mario Santinami, MD
Fondazione Istituto Nazionale Tumori, ItalyAuthored Items
Dirk Schadendorf, MD, Reinhard Dummer, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Christine-Elke Ortmann, MS, Egbert de Jong, MD, Eduard Gasal, MD, Richard Kefford, MD, PhD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
November 2019 Vol 10, No 11
In the COMBI-AD trial (NCT01682083), 12 months of adjuvant D+T led to significant improvement of RFS versus PBO (hazard ratio [HR], 0.47; P <.001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59% and 54%, respectively.
Dirk Schadendorf, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, MD, PhD, Reinhard Dummer, MD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
November 2018 Vol 9, NO 11
Adjuvant treatment (tx) of resected stage III BRAF-mutant melanoma with dabrafenib + trametinib (D+T) significantly reduced the risk of recurrence vs placebo (PBO).
Last modified: November 6, 2019